STOCK TITAN

Novabay Pharma - NBY STOCK NEWS

Welcome to our dedicated page for Novabay Pharma news (Ticker: NBY), a resource for investors and traders seeking the latest updates and insights on Novabay Pharma stock.

NovaBay Pharmaceuticals (NBY) delivers innovative non-antibiotic anti-infectives for ophthalmic care, wound management, and dermatological conditions. This page provides investors and healthcare professionals with timely updates on the company’s scientific advancements, regulatory milestones, and market strategies.

Access consolidated news about NBY’s Neutrox™ product line, including Avenova for chronic eye conditions, and developments in its Aganocide® compound research. Stay informed about financial disclosures, partnership announcements, and clinical trial outcomes through verified press releases and analysis.

Key updates include FDA submissions, international distribution expansions, and peer-reviewed study results. Our repository ensures efficient tracking of NovaBay’s progress in addressing antibiotic resistance challenges through its patented antimicrobial technologies.

Bookmark this page for direct access to NBY’s latest corporate communications. Check regularly for insights into commercialization efforts and research breakthroughs shaping the future of non-antibiotic therapies.

Rhea-AI Summary

NovaBay Pharmaceuticals (NYSE American: NBY) will report its financial results for the fiscal year ending December 31, 2021, on March 29, 2022, after market close. An investment community conference call will follow at 4:30 p.m. ET. Participants can pre-register for the call, which will also be available via live webcast. NovaBay, known for Avenova, the leading antimicrobial lid and lash spray, acquired DERMAdoctor in November 2021, enhancing its product offerings in skincare.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

NovaBay Pharmaceuticals (NYSE American: NBY) announces the launch of its new Moisture Recovery HA Serum, designed specifically for dry, eczema-prone skin. This innovative serum features hyaluronic acid, Vitamin C, and unique botanical ingredients, promising hydration and skin repair. Priced at $48.00 for a 30 ml bottle, the serum is available on Amazon and dermadoctor.com. Dermatologist Dr. Audrey Kunin emphasized its benefits for sensitive skin.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

NovaBay Pharmaceuticals (NYSE American: NBY) announces a feature of its Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm on QVC's "Cheers! to Shopping with Leah and Shawn" on March 1 at 10 p.m. Eastern Time. Chief Product Officer Dr. Audrey Kunin, a board-certified dermatologist, will present the product designed for eczema, affecting 31 million Americans. The balm boasts 1% colloidal oatmeal for skin irritation relief and has received the National Eczema Association Seal of Acceptance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
conferences
Rhea-AI Summary

NovaBay Pharmaceuticals (NBY) has engaged a leading Chinese marketing firm for integrated marketing and branding services for its DERMAdoctor skincare products. This collaboration includes managing DERMAdoctor's retail store on Tmall.com, China's top B2C online retailer, starting March 1, 2022. The marketing strategy aims to enhance brand awareness by leveraging social media and influencers, targeting a burgeoning functional skincare market projected to exceed $100 billion by 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

NovaBay Pharmaceuticals (NBY) has appointed Dr. Audrey Kunin and Julie Garlikov to its Board of Directors, enhancing its leadership in the skincare and eyecare markets. Dr. Kunin, previously Chief Product Officer, has significant experience in product formulation from her time at DERMAdoctor. Garlikov brings over 25 years of marketing expertise in health and beauty, while Yongxiang Zheng fills the vacancy left by Paul Li. The changes are aimed at leveraging industry insights to boost growth in the OTC market. NovaBay sees a path to profitability following the DERMAdoctor acquisition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
none
Rhea-AI Summary

NovaBay Pharmaceuticals has announced that its Special Meeting of Stockholders, initially held on December 17, 2021, is adjourned to January 31, 2022, to gather more votes for Proposal Two. This proposal aims to increase authorized common stock from 100 million to 150 million shares. Although it received significant support, votes were under 50% of the total, not meeting the required threshold. The company plans to resubmit the proposal if it does not pass. Stockholders are urged to vote by January 30 at 11:59 p.m. Eastern time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
none
-
Rhea-AI Summary

NovaBay Pharmaceuticals (NYSE: NBY) expands its Avenova brand with the launch of Avenova Lubricating Eye Drops, targeting the growing dry eye market projected to reach $6.4 billion by 2028. The eye drops are formulated for immediate relief and are priced competitively at $19.99 for a twin pack. NovaBay's regimen includes Avenova Warm Eye Compress and Avenova Lid & Lash Solution, enhancing treatment efficacy. This product launch marks NovaBay's commitment to developing innovative eyecare solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

NovaBay Pharmaceuticals (NYSE American: NBY) will present at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. The company aims to provide insights into its expansion strategy following its acquisition of DERMAdoctor in November 2021. CEO Justin Hall projects sales to double in 2022, driven by the transition of Avenova from prescription to over-the-counter sales and plans to launch at least four new products in the first half of 2022. A webcast of the presentation will be available on the company’s website starting January 10, 2022, at 7:00 a.m. Eastern time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
conferences
Rhea-AI Summary

NovaBay Pharmaceuticals (NBY) has adjourned its Special Meeting of Stockholders, originally held on December 17, 2021, to January 14, 2022. This extension aims to allow more time for stockholders to vote on Proposal Two, which seeks to increase the authorized common stock from 100 million to 150 million shares. Although 83.5% of shares voted supported this proposal, it fell short of the required 50% of all outstanding shares. Stakeholders are encouraged to vote before the reconvened meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Novabay Pharma

NYSE:NBY

NBY Rankings

NBY Stock Data

3.49M
5.82M
0.02%
14.9%
1.82%
Biotechnology
Pharmaceutical Preparations
Link
United States
EMERYVILLE